Month: April 2021

SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into an agreement with East West Bank (“EWB”) in which EWB will provide a $7.5 million working capital line of credit. The line of credit is secured by Journey Medical’s receivables and cash. Interest on the line is the greater of 4.25% or the Prime Rate plus 1%. The agreement expires in 36 months. Journey Medical intends to use the proceeds for general corporate purposes, including the advancement of the Company’s portfolio. Claude Maraoui, President and Chief Executive Officer of Journey Medical, stated, “We are pleased to work with EWB to support our operating needs and future growth ambitions. With access...

– Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options – Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 – Global Phase 1/2 trial – GALax-C – PBKR03 planned to initiate in first half of 2021 PHILADELPHIA, April 05, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). The designation was based on a positive opinion from the European Medicines...

HOUSTON, April 05, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen (BP1001), a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia (AML) patients. The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax. “We are particularly pleased with the clean side effect profile and lack of toxicity...

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued, Company to Focus on Development of Next-Generation ETB Product Candidates Including Clinical Stage MT-5111, TAK-169 and MT-6402 AUSTIN, Texas, April 05, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that, following discussion with its co-development partner Takeda, MTEM will assume full rights to TAK-169 including taking control of clinical development from Takeda. In addition, MTEM announced the decision to...

~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~ ~ Company announces plans to initiate a second clinical study of AMT-130in Europe in the second half of 2021 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 05, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year. “This is an important milestone in our ongoing clinical development of AMT-130,” stated David Cooper, M.D., vice president, clinical...

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021: Needham Virtual Healthcare ConferenceMonday, April 12, 2021 at 12:45 p.m. ETThe live and archived Needham Virtual Healthcare Conference presentation webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.Wet AMD & DME Drug Development SummitWednesday, April 14, 2021Event details are available on the conference website.10:45 a.m. ET – Panel Discussion:...

HARTSVILLE, S.C., April 05, 2021 (GLOBE NEWSWIRE) — Sonoco (NYSE: SON), one of the most diversified global packaging companies, today announced it has closed on the sale of its Display and Packaging business in the United States to Hood Container Corporation for $80 million in cash. Sonoco’s U.S. Display and Packaging business produced net sales of approximately $135 million in 2020 and provides point-of-purchase display design, manufacturing and fulfillment as well as contract packaging services for consumer product customers with more than 250 brands. Based in Winston-Salem, N.C., the Display and Packaging business operates eight manufacturing and fulfillment facilities along with four sales and design centers and has approximately 450 employees. Based in Atlanta, GA, Hood Container is a family owned, leading integrated paperboard...

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with expertise in building and leading commercial teams accompanied by a record of successful product launches. She most recently served as Vice President, Neurological Rare Diseases at Genentech. Ms. Merendino will be a member of Myovant’s Executive Committee, reporting directly to Chief Executive Officer David Marek. “We are thrilled to welcome Lauren, who joins Myovant at a pivotal point following our transition into a commercial-stage company,”...

LARBERT, Scotland, April 05, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI”), one of the world’s leading independent global bus manufacturers, today announced that Berliner Verkehrsbetriebe (“BVG”) has exercised options for 198 Enviro500 double deck buses, to be delivered to the German capital by the end of 2022. Alexander Dennis Limited (“ADL”), a subsidiary of NFI, will build these buses in its factories in the United Kingdom. NFI delivered the first two Enviro500 double deck buses to BVG in October 2020 as part of a multi-year framework contract signed in 2018. Following the successful completion of a testing programme with this initial pair of vehicles, BVG’s supervisory board approved the conversion of options for another 198 buses into firm orders, taking the fleet to 200. Options for an additional 230...